Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non-small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD.

被引：0
|
作者：
Janne, Pasi A.
Ramalingam, Suresh S.
Yang, James Chih-Hsin
Riely, Gregory J.
Bunn, Veronica
Jin, Shu
Zhou, Caicun
Camidge, D. Ross
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
[2] Emory Univ, Atlanta, GA USA
[3] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[4] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, New York, NY USA
[5] Takeda Dev Ctr Americas Inc, Lexington, MA USA
[6] Shanghai Pulm Hosp, Shanghai, Peoples R China
[7] Univ Colorado, Canc Ctr, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9099
引用
收藏
页数：1
相关论文
共 38 条
  • [21] Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial (vol 7, e214761, 2021)
    Zhou, C.
    Ramalingam, S. S.
    Kim, T. M.
    JAMA ONCOLOGY, 2022,
  • [22] Real-World Treatment Outcomes of Amivantamab in Pre-Approval Access (PAA) Participants with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations (ex20ins)
    Sabari, J.
    Kim, T. M.
    Spira, A.
    Lee, S. H.
    Chang, G. C.
    Shih, J. -Y.
    Hochmair, M. J.
    Schioppa, C. A.
    Schioppa, C. A.
    Panaccione, A.
    Rose, J. B.
    Chioda, M.
    Mahadevia, P.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E23 - E23
  • [23] Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)
    Kim, T. M.
    Lee, S-H.
    Chang, G-C.
    Shih, J-Y.
    Hochmair, M. J.
    Sabari, J. K.
    Spira, A. I.
    Schioppa, C. A.
    Rose, J. B.
    Chioda, M.
    Panaccione, A.
    Mahadevia, P.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 : S48 - S48
  • [24] Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial (vol 7, e214761, 2021)
    Feng, Jean
    Friesner, Isabel
    Hong, Julian C.
    JAMA ONCOLOGY, 2024, 10 (10) : 1443 - 1443
  • [25] Efficacy and safety of poziotinib in treatment-naive HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4
    Sun, S.
    Prelaj, A.
    Baik, C.
    Le, X.
    Garassino, M.
    Wollner, M.
    Haura, E.
    Piotrowska, Z.
    Socinski, M.
    Dreiling, L.
    Bhat, G.
    Lebel, F.
    Cornelissen, R.
    ANNALS OF ONCOLOGY, 2022, 33 : S13 - S13
  • [26] Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088
    Loong, H. H. F.
    Daniele, G.
    Yang, T-Y.
    Leal, T. A.
    Goto, K.
    Shinno, Y.
    Nishino, K.
    Sakamoto, T.
    Felip, E.
    Ruffinelli, J. C.
    Gallot, N.
    Wang, Z.
    Chen, C.
    Brennan, B.
    Pu, S-F.
    Kornacker, M.
    Grassi, P.
    Le, X.
    Tan, D. S. W.
    Goh, B-C.
    ANNALS OF ONCOLOGY, 2023, 34
  • [27] A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations
    Yoh, Kiyotaka
    Azuma, Koichi
    Hayashi, Hidetoshi
    Nishio, Makoto
    Chikamori, Kenichi
    Ichihara, Eiki
    Watanabe, Yasutaka
    Asato, Takayuki
    Kitagawa, Tadayuki
    Fram, Robert J.
    Ohe, Yuichiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (10) : 1461 - 1474
  • [28] Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study
    Liu, Geoffrey
    Nyaw, Shi Feng
    Mok, Tony S. K.
    Curcio, Hubert
    Cortot, Alexis B.
    Kam, Tsz Yeung
    Descourt, Renaud
    Chik, Yin Kwan
    Cheema, Parneet
    Gwinnutt, James M.
    Churchill, Eric N.
    Nyborn, Justin
    Curran, Eileen
    Savell, Alexandra
    Yin, Yu
    Chong, Katie
    Tanaka-Chambers, Yuka
    Kretz, Julian
    Cadranel, Jacques
    CANCER MEDICINE, 2025, 14 (03):
  • [29] Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positivemetastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial (vol 7, e214761, 2021)
    Zhou, C.
    Ramalingam, S. S.
    Kim, T. M.
    JAMA ONCOLOGY, 2022, 8 (09) : 1359 - 1359
  • [30] Real-world treatment duration in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (EGFRex20ins) mutations receiving mobocertinib through the global Expanded Access Program (EAP)
    Lee, V. H. F.
    Lin, M.
    Curran, E.
    Yin, Y.
    Churchill, E.
    Allen, S.
    Abovich, J.
    Leighl, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1059 - S1059
1234